{"id":3123,"date":"2016-02-22T06:54:18","date_gmt":"2016-02-22T06:54:18","guid":{"rendered":"http:\/\/www.medicalmarijuanainc.com\/?p=5936"},"modified":"2016-02-22T06:54:18","modified_gmt":"2016-02-22T06:54:18","slug":"medical-marijuana-inc-portfolio-investment-company-kannalife-sciences-inc-receives-publication-through-american-chemical-society-for-kls-13019-a-novel-cannabidiol-derived-target-drug-candidate-f","status":"publish","type":"post","link":"https:\/\/medicalmarijuanainc.com\/2016\/02\/22\/medical-marijuana-inc-portfolio-investment-company-kannalife-sciences-inc-receives-publication-through-american-chemical-society-for-kls-13019-a-novel-cannabidiol-derived-target-drug-candidate-f\/","title":{"rendered":"Medical Marijuana, Inc. Portfolio Investment Company, Kannalife Sciences, Inc. Receives Publication through American Chemical Society for KLS-13019, a Novel Cannabidiol-Derived Target Drug Candidate for Hepatic Encephalopathy"},"content":{"rendered":"<h3><strong><em>Kannalife Sciences, Inc., a Phyto-Medical Company\u2122 has found through its research that KLS-13019\u00a0is 50x More Potent and Over 400-Fold Safer Than CBD<\/em><\/strong><\/h3>\n<p>SAN DIEGO, CA \u2013 February 18, 2016 \u2013 Medical Marijuana, Inc. (OTC Pink: MJNA) is pleased to\u00a0announce that the Company\u2019s portfolio investment company, <a href=\"https:\/\/medicalmarijuanainc.com\/companies\/kannalife\/\">Kannalife Sciences, Inc<\/a>. (\u201cKannalife\u201d),\u00a0has made a major breakthrough in the field for cannabinoid therapeutics with the publication of the\u00a0body of science behind the new cannabidiol (CBD)-like molecule KLS-13019. The abstract, as well as\u00a0the purchase of the full version of the publication on the \u201cDiscovery of KLS-13019\u201d is available online\u00a0at: <a href=\"http:\/\/pubs.acs.org\/doi\/abs\/10.1021\/acsmedchemlett.6b00009\" target=\"_blank\" rel=\"noopener\">http:\/\/pubs.acs.org\/doi\/abs\/10.1021\/acsmedchemlett.6b00009<\/a>.<\/p>\n<p>\u201cWe are very excited to see the progress being made at Kannalife toward their pharmaceutical\u00a0development of cannabinoid-derived therapeutic agents,\u201d states <a href=\"https:\/\/medicalmarijuanainc.com\/company\/#leadership\" target=\"_blank\" rel=\"noopener\">Dr. Stuart W. Titus<\/a>, Chief Executive\u00a0Officer of Medical Marijuana, Inc. \u201cWith the development of KLS-13019, there is potential for orphan\u00a0drug designation in Grade 3 <a href=\"https:\/\/medicalmarijuanainc.com\/hepatic-encephalopathy-overview\/\" target=\"_blank\" rel=\"noopener\">hepatic encephalopathy<\/a> (HE). Pre-clinical studies have led Kannalife\u2019s\u00a0scientific team to believe KLS-13019 may successfully provide answers for late-stage HE patients.\u201d<\/p>\n<p>Through pre-clinical testing and pharmacokinetic (PK) studies, Kannalife\u2019s findings indicate\u00a0improvement over CBD\u2019s role as a neuroprotectant in both increased potency and reduction of toxicity.\u00a0Side-by-side comparisons between CBD and KLS-13019 have also shown that KLS-13019 has marked\u00a0improvements over CBD in oral bioavailability, CNS penetration, blood-plasma concentrations, and\u00a0cognitive improvement in pilot murine behavioral models. The published findings explain that KLS-13019 was 50-fold more potent and &gt;400-fold safer than <a href=\"https:\/\/medicalmarijuanainc.com\/what-is-cbd-oil\/\" target=\"_blank\" rel=\"noopener\">cannabidiol<\/a> (CBD) and exhibited an improved\u00a0in vitro profile consistent with improved oral bioavailability.<\/p>\n<p>Titus continues, \u201cThe potential for KLS-13019 and its significance stands beyond its intended target of\u00a0ameliorating neurodegeneration brought on by ethanol and ammonium toxicity but also its potential in\u00a0repairing <a href=\"https:\/\/medicalmarijuanainc.com\/liver-disorders-medical-marijuana-research-overview\/\" target=\"_blank\" rel=\"noopener\">liver<\/a> damage brought on by cirrhosis. A successful clinical trial may also lead to other\u00a0important areas such as the use of KLS-13019 as a possible adjuvant as a long-term solution for drug-induced liver disease.\u201d<\/p>\n<p>Drug-induced liver toxicity (DILI) is a common cause of liver injury. It accounts for approximately one-half of the cases of acute liver failure and mimics all forms of acute and chronic liver disease. An\u00a0estimated 1,000 drugs have been implicated in causing liver disease on greater than one occasion.<\/p>\n<p>Although, with the exception of rare cases, drug-induced liver injury subsides after cessation of\u00a0treatment with the drug, this represents an important diagnostic and therapeutic challenge for\u00a0physicians.<\/p>\n<p>About Kannalife Sciences, Inc.<\/p>\n<p><a href=\"https:\/\/medicalmarijuanainc.com\/companies\/kannalife\/\" target=\"_blank\" rel=\"noopener\">Kannalife Sciences, Inc.<\/a> is a phyto-medical company involved in the research and development of novel\u00a0therapeutic agents designed to be neuroprotectants and immuno-modulators. Kannalife is currently\u00a0conducting research and development at the Pennsylvania Biotechnology Center in Doylestown, PA,\u00a0for target drug candidates to treat Hepatic Encephalopathy (\u201cHE\u201d) and Chronic Traumatic\u00a0Encephalopathy (\u201cCTE\u201d). HE and CTE are oxidative stress related diseases that affect cognitive and\u00a0behavioral functions. For more information, visit: www.Kannalife.com.<\/p>\n<p>About Medical Marijuana Inc.<\/p>\n<p>The mission of Medical Marijuana, Inc. (OTC Pink: MJNA) is to be the premier cannabis and hemp\u00a0industry innovator, leveraging our team of professionals to source, evaluate and purchase value-added\u00a0companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive\u00a0to create awareness within our industry, develop environmentally-friendly, economically sustainable\u00a0businesses, while increasing shareholder value.<\/p>\n<p>FOOD AND DRUG ADMINISTRATION (FDA) DISCLOSURE<\/p>\n<p>These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure\u00a0any disease.<\/p>\n<p>FORWARD-LOOKING DISCLAIMER<\/p>\n<p>This press release may contain certain forward-looking statements and information, as defined within\u00a0the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange\u00a0Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains\u00a0statements about expected future events and\/or financial results that are forward-looking in nature and\u00a0subject to risks and uncertainties. Such forward-looking statements by definition involve risks,\u00a0uncertainties and other factors, which may cause the actual results, performance or achievements of\u00a0Medical Marijuana, Inc. to be materially different from the statements made herein.<\/p>\n<p>LEGAL DISCLOSURE<\/p>\n<p>Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States\u00a0Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp-based\u00a0products and are involved with the federally legal distribution of medical marijuana-based products\u00a0within certain international markets. Cannabidiol is a natural constituent of hemp oil.    \t<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Kannalife Sciences, Inc., a Phyto-Medical Company\u2122 has found through its research that KLS-13019\u00a0is 50x More Potent and Over 400-Fold Safer Than CBD SAN DIEGO, CA \u2013 February 18, 2016 \u2013 Medical Marijuana, Inc. (OTC Pink: MJNA) is pleased to\u00a0announce that the Company\u2019s portfolio investment company, Kannalife Sciences, Inc. (\u201cKannalife\u201d),\u00a0has made a major breakthrough in the [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2919,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[3,163,2],"tags":[179],"class_list":["post-3123","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company-news","category-kannalife-sciences","category-press-releases","tag-kannalife-sciences"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v20.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Kannalife\u2019s Cannabis Research | Medical Marijuana Inc.<\/title>\n<meta name=\"description\" content=\"Kannalife\u2019s findings indicate improvement over CBD\u2019s role as a neuroprotectant in both increased potency and reduction of toxicity.\" \/>\n<meta name=\"robots\" content=\"noindex, follow\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Kannalife\u2019s Cannabis Research | Medical Marijuana Inc.\" \/>\n<meta property=\"og:description\" content=\"Kannalife\u2019s findings indicate improvement over CBD\u2019s role as a neuroprotectant in both increased potency and reduction of toxicity.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/medicalmarijuanainc.com\/2016\/02\/22\/medical-marijuana-inc-portfolio-investment-company-kannalife-sciences-inc-receives-publication-through-american-chemical-society-for-kls-13019-a-novel-cannabidiol-derived-target-drug-candidate-f\/\" \/>\n<meta property=\"og:site_name\" content=\"Medical Marijuana, Inc.\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/MJNAInc\" \/>\n<meta property=\"article:published_time\" content=\"2016-02-22T06:54:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/medicalmarijuanainc.com\/wp-content\/uploads\/2016\/03\/klifemolecule.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"adminTorusBrand\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@mjna_inc\" \/>\n<meta name=\"twitter:site\" content=\"@mjna_inc\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"adminTorusBrand\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/medicalmarijuanainc.com\/2016\/02\/22\/medical-marijuana-inc-portfolio-investment-company-kannalife-sciences-inc-receives-publication-through-american-chemical-society-for-kls-13019-a-novel-cannabidiol-derived-target-drug-candidate-f\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/medicalmarijuanainc.com\/2016\/02\/22\/medical-marijuana-inc-portfolio-investment-company-kannalife-sciences-inc-receives-publication-through-american-chemical-society-for-kls-13019-a-novel-cannabidiol-derived-target-drug-candidate-f\/\"},\"author\":{\"name\":\"adminTorusBrand\",\"@id\":\"https:\/\/medicalmarijuanainc.com\/#\/schema\/person\/bd5fa0cf1483b68c6bd5c117e3d4242c\"},\"headline\":\"Medical Marijuana, Inc. Portfolio Investment Company, Kannalife Sciences, Inc. Receives Publication through American Chemical Society for KLS-13019, a Novel Cannabidiol-Derived Target Drug Candidate for Hepatic Encephalopathy\",\"datePublished\":\"2016-02-22T06:54:18+00:00\",\"dateModified\":\"2016-02-22T06:54:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/medicalmarijuanainc.com\/2016\/02\/22\/medical-marijuana-inc-portfolio-investment-company-kannalife-sciences-inc-receives-publication-through-american-chemical-society-for-kls-13019-a-novel-cannabidiol-derived-target-drug-candidate-f\/\"},\"wordCount\":754,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/medicalmarijuanainc.com\/#organization\"},\"keywords\":[\"Kannalife Sciences\"],\"articleSection\":[\"Company News\",\"Kannalife Sciences\",\"Press Releases\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/medicalmarijuanainc.com\/2016\/02\/22\/medical-marijuana-inc-portfolio-investment-company-kannalife-sciences-inc-receives-publication-through-american-chemical-society-for-kls-13019-a-novel-cannabidiol-derived-target-drug-candidate-f\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/medicalmarijuanainc.com\/2016\/02\/22\/medical-marijuana-inc-portfolio-investment-company-kannalife-sciences-inc-receives-publication-through-american-chemical-society-for-kls-13019-a-novel-cannabidiol-derived-target-drug-candidate-f\/\",\"url\":\"https:\/\/medicalmarijuanainc.com\/2016\/02\/22\/medical-marijuana-inc-portfolio-investment-company-kannalife-sciences-inc-receives-publication-through-american-chemical-society-for-kls-13019-a-novel-cannabidiol-derived-target-drug-candidate-f\/\",\"name\":\"Kannalife\u2019s Cannabis Research | Medical Marijuana Inc.\",\"isPartOf\":{\"@id\":\"https:\/\/medicalmarijuanainc.com\/#website\"},\"datePublished\":\"2016-02-22T06:54:18+00:00\",\"dateModified\":\"2016-02-22T06:54:18+00:00\",\"description\":\"Kannalife\u2019s findings indicate improvement over CBD\u2019s role as a neuroprotectant in both increased potency and reduction of toxicity.\",\"breadcrumb\":{\"@id\":\"https:\/\/medicalmarijuanainc.com\/2016\/02\/22\/medical-marijuana-inc-portfolio-investment-company-kannalife-sciences-inc-receives-publication-through-american-chemical-society-for-kls-13019-a-novel-cannabidiol-derived-target-drug-candidate-f\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/medicalmarijuanainc.com\/2016\/02\/22\/medical-marijuana-inc-portfolio-investment-company-kannalife-sciences-inc-receives-publication-through-american-chemical-society-for-kls-13019-a-novel-cannabidiol-derived-target-drug-candidate-f\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/medicalmarijuanainc.com\/2016\/02\/22\/medical-marijuana-inc-portfolio-investment-company-kannalife-sciences-inc-receives-publication-through-american-chemical-society-for-kls-13019-a-novel-cannabidiol-derived-target-drug-candidate-f\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/medicalmarijuanainc.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medical Marijuana, Inc. Portfolio Investment Company, Kannalife Sciences, Inc. Receives Publication through American Chemical Society for KLS-13019, a Novel Cannabidiol-Derived Target Drug Candidate for Hepatic Encephalopathy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/medicalmarijuanainc.com\/#website\",\"url\":\"https:\/\/medicalmarijuanainc.com\/\",\"name\":\"Medical Marijuana, Inc.\",\"description\":\"We are a company of firsts\u00ae\ufe0f. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space. Through its subsidiaries, Medical Marijuana, Inc. manufacturers and sells some of the best cannabidiol (CBD), and other cannabinoid-based products, available!\",\"publisher\":{\"@id\":\"https:\/\/medicalmarijuanainc.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/medicalmarijuanainc.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/medicalmarijuanainc.com\/#organization\",\"name\":\"Medical Marijuana, Inc.\",\"url\":\"https:\/\/medicalmarijuanainc.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medicalmarijuanainc.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/medicalmarijuanainc.com\/wp-content\/uploads\/2023\/02\/cropped-logo-medical-marijuana-inc.png\",\"contentUrl\":\"https:\/\/medicalmarijuanainc.com\/wp-content\/uploads\/2023\/02\/cropped-logo-medical-marijuana-inc.png\",\"width\":512,\"height\":512,\"caption\":\"Medical Marijuana, Inc.\"},\"image\":{\"@id\":\"https:\/\/medicalmarijuanainc.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/MJNAInc\",\"https:\/\/twitter.com\/mjna_inc\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/medicalmarijuanainc.com\/#\/schema\/person\/bd5fa0cf1483b68c6bd5c117e3d4242c\",\"name\":\"adminTorusBrand\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/medicalmarijuanainc.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/a912c97701c52370233e20a0d17ab853?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/a912c97701c52370233e20a0d17ab853?s=96&d=mm&r=g\",\"caption\":\"adminTorusBrand\"},\"sameAs\":[\"https:\/\/medicalmarijuanainc.com\"],\"url\":\"https:\/\/medicalmarijuanainc.com\/author\/admintorusbrand\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Kannalife\u2019s Cannabis Research | Medical Marijuana Inc.","description":"Kannalife\u2019s findings indicate improvement over CBD\u2019s role as a neuroprotectant in both increased potency and reduction of toxicity.","robots":{"index":"noindex","follow":"follow"},"og_locale":"en_US","og_type":"article","og_title":"Kannalife\u2019s Cannabis Research | Medical Marijuana Inc.","og_description":"Kannalife\u2019s findings indicate improvement over CBD\u2019s role as a neuroprotectant in both increased potency and reduction of toxicity.","og_url":"https:\/\/medicalmarijuanainc.com\/2016\/02\/22\/medical-marijuana-inc-portfolio-investment-company-kannalife-sciences-inc-receives-publication-through-american-chemical-society-for-kls-13019-a-novel-cannabidiol-derived-target-drug-candidate-f\/","og_site_name":"Medical Marijuana, Inc.","article_publisher":"https:\/\/www.facebook.com\/MJNAInc","article_published_time":"2016-02-22T06:54:18+00:00","og_image":[{"width":1200,"height":500,"url":"https:\/\/medicalmarijuanainc.com\/wp-content\/uploads\/2016\/03\/klifemolecule.jpg","type":"image\/jpeg"}],"author":"adminTorusBrand","twitter_card":"summary_large_image","twitter_creator":"@mjna_inc","twitter_site":"@mjna_inc","twitter_misc":{"Written by":"adminTorusBrand","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/medicalmarijuanainc.com\/2016\/02\/22\/medical-marijuana-inc-portfolio-investment-company-kannalife-sciences-inc-receives-publication-through-american-chemical-society-for-kls-13019-a-novel-cannabidiol-derived-target-drug-candidate-f\/#article","isPartOf":{"@id":"https:\/\/medicalmarijuanainc.com\/2016\/02\/22\/medical-marijuana-inc-portfolio-investment-company-kannalife-sciences-inc-receives-publication-through-american-chemical-society-for-kls-13019-a-novel-cannabidiol-derived-target-drug-candidate-f\/"},"author":{"name":"adminTorusBrand","@id":"https:\/\/medicalmarijuanainc.com\/#\/schema\/person\/bd5fa0cf1483b68c6bd5c117e3d4242c"},"headline":"Medical Marijuana, Inc. Portfolio Investment Company, Kannalife Sciences, Inc. Receives Publication through American Chemical Society for KLS-13019, a Novel Cannabidiol-Derived Target Drug Candidate for Hepatic Encephalopathy","datePublished":"2016-02-22T06:54:18+00:00","dateModified":"2016-02-22T06:54:18+00:00","mainEntityOfPage":{"@id":"https:\/\/medicalmarijuanainc.com\/2016\/02\/22\/medical-marijuana-inc-portfolio-investment-company-kannalife-sciences-inc-receives-publication-through-american-chemical-society-for-kls-13019-a-novel-cannabidiol-derived-target-drug-candidate-f\/"},"wordCount":754,"commentCount":0,"publisher":{"@id":"https:\/\/medicalmarijuanainc.com\/#organization"},"keywords":["Kannalife Sciences"],"articleSection":["Company News","Kannalife Sciences","Press Releases"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/medicalmarijuanainc.com\/2016\/02\/22\/medical-marijuana-inc-portfolio-investment-company-kannalife-sciences-inc-receives-publication-through-american-chemical-society-for-kls-13019-a-novel-cannabidiol-derived-target-drug-candidate-f\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/medicalmarijuanainc.com\/2016\/02\/22\/medical-marijuana-inc-portfolio-investment-company-kannalife-sciences-inc-receives-publication-through-american-chemical-society-for-kls-13019-a-novel-cannabidiol-derived-target-drug-candidate-f\/","url":"https:\/\/medicalmarijuanainc.com\/2016\/02\/22\/medical-marijuana-inc-portfolio-investment-company-kannalife-sciences-inc-receives-publication-through-american-chemical-society-for-kls-13019-a-novel-cannabidiol-derived-target-drug-candidate-f\/","name":"Kannalife\u2019s Cannabis Research | Medical Marijuana Inc.","isPartOf":{"@id":"https:\/\/medicalmarijuanainc.com\/#website"},"datePublished":"2016-02-22T06:54:18+00:00","dateModified":"2016-02-22T06:54:18+00:00","description":"Kannalife\u2019s findings indicate improvement over CBD\u2019s role as a neuroprotectant in both increased potency and reduction of toxicity.","breadcrumb":{"@id":"https:\/\/medicalmarijuanainc.com\/2016\/02\/22\/medical-marijuana-inc-portfolio-investment-company-kannalife-sciences-inc-receives-publication-through-american-chemical-society-for-kls-13019-a-novel-cannabidiol-derived-target-drug-candidate-f\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/medicalmarijuanainc.com\/2016\/02\/22\/medical-marijuana-inc-portfolio-investment-company-kannalife-sciences-inc-receives-publication-through-american-chemical-society-for-kls-13019-a-novel-cannabidiol-derived-target-drug-candidate-f\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/medicalmarijuanainc.com\/2016\/02\/22\/medical-marijuana-inc-portfolio-investment-company-kannalife-sciences-inc-receives-publication-through-american-chemical-society-for-kls-13019-a-novel-cannabidiol-derived-target-drug-candidate-f\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/medicalmarijuanainc.com\/"},{"@type":"ListItem","position":2,"name":"Medical Marijuana, Inc. Portfolio Investment Company, Kannalife Sciences, Inc. Receives Publication through American Chemical Society for KLS-13019, a Novel Cannabidiol-Derived Target Drug Candidate for Hepatic Encephalopathy"}]},{"@type":"WebSite","@id":"https:\/\/medicalmarijuanainc.com\/#website","url":"https:\/\/medicalmarijuanainc.com\/","name":"Medical Marijuana, Inc.","description":"We are a company of firsts\u00ae\ufe0f. Medical Marijuana, Inc. (MJNA) is a cannabis company with three distinct business units in the non-psychoactive cannabinoid space. Through its subsidiaries, Medical Marijuana, Inc. manufacturers and sells some of the best cannabidiol (CBD), and other cannabinoid-based products, available!","publisher":{"@id":"https:\/\/medicalmarijuanainc.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/medicalmarijuanainc.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/medicalmarijuanainc.com\/#organization","name":"Medical Marijuana, Inc.","url":"https:\/\/medicalmarijuanainc.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medicalmarijuanainc.com\/#\/schema\/logo\/image\/","url":"https:\/\/medicalmarijuanainc.com\/wp-content\/uploads\/2023\/02\/cropped-logo-medical-marijuana-inc.png","contentUrl":"https:\/\/medicalmarijuanainc.com\/wp-content\/uploads\/2023\/02\/cropped-logo-medical-marijuana-inc.png","width":512,"height":512,"caption":"Medical Marijuana, Inc."},"image":{"@id":"https:\/\/medicalmarijuanainc.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/MJNAInc","https:\/\/twitter.com\/mjna_inc"]},{"@type":"Person","@id":"https:\/\/medicalmarijuanainc.com\/#\/schema\/person\/bd5fa0cf1483b68c6bd5c117e3d4242c","name":"adminTorusBrand","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/medicalmarijuanainc.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/a912c97701c52370233e20a0d17ab853?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a912c97701c52370233e20a0d17ab853?s=96&d=mm&r=g","caption":"adminTorusBrand"},"sameAs":["https:\/\/medicalmarijuanainc.com"],"url":"https:\/\/medicalmarijuanainc.com\/author\/admintorusbrand\/"}]}},"_links":{"self":[{"href":"https:\/\/medicalmarijuanainc.com\/wp-json\/wp\/v2\/posts\/3123","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicalmarijuanainc.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medicalmarijuanainc.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medicalmarijuanainc.com\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/medicalmarijuanainc.com\/wp-json\/wp\/v2\/comments?post=3123"}],"version-history":[{"count":0,"href":"https:\/\/medicalmarijuanainc.com\/wp-json\/wp\/v2\/posts\/3123\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medicalmarijuanainc.com\/wp-json\/wp\/v2\/media\/2919"}],"wp:attachment":[{"href":"https:\/\/medicalmarijuanainc.com\/wp-json\/wp\/v2\/media?parent=3123"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medicalmarijuanainc.com\/wp-json\/wp\/v2\/categories?post=3123"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medicalmarijuanainc.com\/wp-json\/wp\/v2\/tags?post=3123"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}